Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability
…, N Malavolta, L Bernini, E Cacace, L Sinigaglia… - Arthritis research & …, 2010 - Springer
Introduction The aim of this study was to estimate the prevalence and determinants of vitamin
D deficiency in patients with rheumatoid arthritis (RA) as compared to healthy controls and …
D deficiency in patients with rheumatoid arthritis (RA) as compared to healthy controls and …
A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis.
L Sinigaglia, A Nervetti, Q Mela, G Bianchi… - The journal of …, 2000 - europepmc.org
Objective To determine the frequency of osteoporosis in a large cohort of women with
rheumatoid arthritis (RA) and to investigate the main determinants of bone mineral density (BMD) …
rheumatoid arthritis (RA) and to investigate the main determinants of bone mineral density (BMD) …
Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study.
…, M Bevilacqua, P Bettica, L Sinigaglia - The Journal of …, 2000 - europepmc.org
Objective To evaluate the efficacy of intravenous (iv) clodronate in patients with reflex
sympathetic dystrophy syndrome (RSDS) and to assess the urinary excretion of type I collagen …
sympathetic dystrophy syndrome (RSDS) and to assess the urinary excretion of type I collagen …
Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study
…, L Idolazzi, F Zucchi, N Malavolta, L Sinigaglia - …, 2013 - academic.oup.com
Objective. Complex regional pain syndrome type I (CRPS-I) is a severely disabling pain
syndrome for which no definite treatment has been established. The aim of this multi-centre, …
syndrome for which no definite treatment has been established. The aim of this multi-centre, …
Association between iron overload and osteoporosis in patients with hereditary hemochromatosis
…, AL Fracanzani, V Rossi, S Fargion, L Sinigaglia - Osteoporosis …, 2009 - Springer
In 87 patients with hereditary hemochromatosis, osteoporosis was detected in 25%, and
osteopenia in 41%. Bone mineral density was independently associated with BMI, ALP levels, …
osteopenia in 41%. Bone mineral density was independently associated with BMI, ALP levels, …
Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course
…, E Fusaro, S Parisi, L Sinigaglia… - Journal of clinical …, 2019 - mdpi.com
Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the
occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung …
occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung …
Transcript imaging of the development of human T helper cells using oligonucleotide arrays
…, L Sinigaglia, M Seiler, M Neeb, J Mous, F Sinigaglia… - nature genetics, 2000 - nature.com
Many pathological processes, including those causing allergies and autoimmune diseases,
are associated with the presence of specialized subsets of T helper cells at the site of …
are associated with the presence of specialized subsets of T helper cells at the site of …
Epidemiology of osteoporosis in rheumatic diseases
L Sinigaglia, M Varenna… - Rheumatic Disease …, 2006 - rheumatic.theclinics.com
Osteoporosis and related fragility fractures are one of the most common complications that
occur in patients who have rheumatic diseases, and they contribute to a dramatic decrease in …
occur in patients who have rheumatic diseases, and they contribute to a dramatic decrease in …
Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial
…, R Mulè, I Pantano, I Prevete, L Sinigaglia… - PLoS …, 2019 - journals.plos.org
Background The inflammatory contribution to type 2 diabetes (T2D) has suggested new
therapeutic targets using biologic drugs designed for rheumatoid arthritis (RA). On this basis, we …
therapeutic targets using biologic drugs designed for rheumatoid arthritis (RA). On this basis, we …
Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study
…, G Luisetto, S Minisola, L Sinigaglia… - Journal of Bone and …, 2006 - academic.oup.com
None of the available osteoporosis therapies have been shown to completely abolish the
risk of fractures. In clinical practice, the outcome may be even poorer. In 880 patients …
risk of fractures. In clinical practice, the outcome may be even poorer. In 880 patients …